IPO Details
Bidding Dates
16 May '23 - 18 May '23
Minimum Investment
₹122,900 / 1 Lots (100 Shares)
Price Range
₹1150 - ₹1229
Maximum Investment
₹122,900 / 1 Lots (100 Shares)
Retail Discount
Not Applicable
Issue Size
₹47.69 crore
Investor category and sub category
Qualified Institutional Buyers | Non-Institutional Investors | Retail Individual Investor |IPO Dates
Important dates with respect to IPO allotment and listing
Opening Date
May 16, 2023
Closing Date
May 18, 2023
Basis of Allotment
May 23, 2023
Initiation of Refunds
May 24, 2023
Credit of Shares to Demat
May 25, 2023
Listing Date
May 28, 2023
UPI Mandatory Expiry Date
May 18, 2023
Remus Pharmaceuticals IPO Subscription Details
| Date | QIB | NII | Retail | Total |
|---|---|---|---|---|
Day 1May 16, 2023 |
0.00 | 2.85 | 2.85 | 1.43 |
Day 2May 17, 2023 |
1.48 | 12.25 | 10.93 | 6.41 |
Day 3May 18, 2023 |
1.48 | 33.16 | 17.21 | 11.74 |
Remus Pharmaceuticals IPO Subscription Status Live
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutions Buyer | 1.48 |
| Non-Institutional Buyers | 33.16 |
| Retail Investors | 17.21 |
| Employees | [.] |
| Others | [.] |
| Total | 11.74 |
About Remus Pharmaceuticals Limited IPO
Remus Pharmaceuticals participates in the marketing and distribution of finished formulations of pharmaceutical drugs. Its business line can be classified into three major categories.
- API marketing and distribution
- Finished pharmaceutical drugs: marketing and distribution
- Technical consultancy to prepare reports on pharmaceutical dossiers
Remus Pharma distributes to generic distributors, and regional and multinational distributors to hospitals and clinics through a responsive distribution channel. It caters to clients spread across twenty countries.
As on January 31, 2023, Remus Pharma had a product portfolio of 429 products that it sells under different brand names in different countries.
Remus Pharmaceuticals Limited IPO Details
The IPO contains only fresh issues worth Rs. 47.69. In the book-building IPO, the price band is fixed at Rs. 1150-1229 per share. The bidding window will open on May 17, 2023, for retail investors.
Remus Pharmaceuticals Limited IPO Objective
The net proceeds from the fresh issues will be utilised in the areas below.
- Funding investment for an acquisition
- General corporate purposes and working capital requirements
- To meet the IPO expenses
Should you invest in Remus Pharmaceuticals Limited?
Here are a few key reasons to consider before investing in the IPO:
- The company offers a diversified product portfolio to its customers spread across 20 countries.
- Remus Pharma has a diversified business operation and revenue base.
- It is engaged with contract manufacturers that are WHO and GMP-compliant.
Competitive Peers
The other players in the segment recognised by the company are Trident Lifeline, Vaishali Pharma, and Chandra Bhagat Pharma Ltd.
Noteworthy Highlights of Remus Pharmaceuticals Limited
- The revenue from export has increased from Rs. 1,191.90 lakhs in FY 2020 to Rs. 2,316.23 lakhs in FY 2022.
IPO Financials
| Particulars | Period ending on December 31, 2022 | Year ending on March 31, 2022 | Year ending on March 31, 2021 |
|---|---|---|---|
| Revenue from Operations | 3,239.17 | 2,471.71 | 1,841.81 |
| Profit After Tax (PAT) | 643.90 | 338.57 | 102.58 |
| PAT Margin | 19.88% | 13.70% | 5.57% |
| EBITDA | 916.17 | 479.07 | 156.82 |
| EBITDA Margin | 28.28% | 19.38% | 8.51% |
| ROE | 54.68% | 71.44% | 40.49% |
Know before investing
Strengths
3-
It operates on a scalable business model.
-
The promoters are experienced in the pharmaceutical industry.
-
The company offers a wide product base of 429 products, with an additional 134 products in the process of registration in 16 countries.
Risks
3-
Dependency on suppliers and manufacturers can impact the company’s future business operations and financial performance.
-
The company lacks brand awareness.
-
The absence of steady cash flow and the non-availability of funds can impact the future performance and profitability of the business.
Login to Angel One App / Website & click on IPO
Select desired IPO & tap on "Apply"
Enter UPI ID, set quantity/price & submit
Accept mandate on the UPI app to complete the process
Login to Angel One App / Website
Choose IPO section on Home Page
Click IPO Orders
Chose the IPO application you want to view the status for
Remus Pharmaceuticals Limited IPO FAQs
The Remus Pharmaceuticals Limited IPO consists of fresh issues worth Rs. 47.69 crore. The Remus Pharmaceuticals Limited IPO price band is fixed at Rs. 1150–1229 per share.
The Basis of Allotment date for Remus Pharmaceuticals Limited is May 24, 2023.
Retail investors can apply for one lot with 100 shares.
The IPO bidding window will open on May 17, 2023.
Retail investors can apply for a minimum of one lot.
The Remus Pharmaceuticals Limited IPO will list on the exchange on May 29, 2023.
You can check the Remus Pharmaceuticals Limited IPO allotment status on Angel One’s mobile app. Log in to the app using your registered mobile number and verification OTP. To check IPO shares’ allotment status, enter the application number, DP ID, and PAN number into the app to check the allotment status.
Listing gains can be ascertained on the day of listing the IPO on the stock exchange, which is May 29, 2023, in the case of Remus Pharmaceuticals Limited.
The bank will only block the amount in your account. The money will not be debited before the IPO shares are allotted.
To approve the payment mandate, log in to your UPI handle. You will receive a payment request on the UPI payment platform. Approve the request.
You can submit only one application using one PAN card.
The minimum order quantity is one lot with 100 shares.
